SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project with an active developer, attracting attention from investors looking to move beyond typical pump-and-dump cycles. The community is actively pushing for mainstream platform visibility and increased trading volume to support their long-term goal of hitting significant market cap milestones.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum and trending as investors react to a strategic payroll infrastructure partnership with Stellar, fueling optimism for broader institutional adoption. The community is actively discussing the potential for future XRP collaboration and a possible Coinbase listing, with many using the current price consolidation as a strategic accumulation phase.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing heightened investor interest driven by a combination of its ongoing strategic pivot into pharmaceutical manufacturing, a fortified balance sheet, and market speculation regarding potential domestic supply chain contracts. Community discussion remains heavily focused on the company's turnaround progress, its status as a potential beneficiary of new pharmaceutical import tariffs, and bullish long-term value projections based on its infrastructure and asset base.

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Grace Therapeutics is gaining momentum as investors anticipate the upcoming PDUFA date for its drug candidate GTx-104. The community is focused on the potential for institutional accumulation and the stock's low float, with many discussing the strategic value of the asset as the company nears its regulatory catalyst.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened social media activity and trading volume driven by investor interest in its post-quantum cryptography features and recent institutional developments, including a shift toward US-based operations. The community remains deeply divided, with long-term holders expressing conviction in the project's technology and future adoption, while active traders continue to debate its recent price volatility and past performance relative to broader market trends.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is currently drawing significant attention as investors shift toward defensive, high-quality dividend compounders amid broader market volatility. The community is actively debating whether the stock's current price levels represent a strategic accumulation point for long-term wealth building or a potential value trap as the company navigates ongoing cost-savings initiatives.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and active call buying as the community debates potential short-squeeze dynamics and the impact of a high short interest against an anticipated operational turnaround. Traders are closely monitoring the stock's price action around critical technical levels, fueled by speculation regarding activist interest and upcoming earnings, while opinions remain sharply divided on the company's long-term sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagar Cements partners Sow & Reap for biochar & gasification units at cement plants

India Business News: HYDERABAD: Climate-tech company Sow & Reap Chara Pvt Ltd and Sagar Cements Limited have signed a 10-year offtake agreement to deploy integrated bi.

Hyderabad: Sow & Reap Chara, Sagar Cements partner to set up biochar, gasification units in Mattampally

The project will substitute fossil fuels with biomass-derived syngas to provide heat for cement manufacturing.

Brief India: The Beat Ideas: Dharmaj Crop Guard - From Capex Drag to Operating Leverage Propellant and more

In this briefing: The Beat Ideas: Dharmaj Crop Guard - From Capex Drag to Operating Leverage Propellant Primer: SG Mart (SGMART IN) - Nov 2025 APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics Why Biocon's Merger Is the Cleaner, Cheaper Path to Value Unlock? Primer: Sagar Cements (SGC IN) - Nov 2025 1. The Beat Ideas: Dharmaj Crop Guard - From Capex Drag to Operating Leverage Propellant Dharmaj Crop Guard had commissioned its INR 275 crore Active Ingredients (AI) plant, cementing its transformation from a formulations-only company to a fully integrated AgroChem player. This strategic backward integration provides a massive new growth lever . However, it came at a short-term cost, as "front-loaded expenses " resulting in EBITDA losses from new plant last year. With the new plant's losses absorbed, Dharmaj is positioned to leverage its integrated model , a pan-India distribution network, to pursue its ambition of becoming a 2,000 crore company by 2030. 2.

Brief India: Primer: SG Mart (SGMART IN) - Nov 2025 and more

In this briefing: Primer: SG Mart (SGMART IN) - Nov 2025 APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics Why Biocon's Merger Is the Cleaner, Cheaper Path to Value Unlock? Primer: Sagar Cements (SGC IN) - Nov 2025 Primer: Olectra Greentech (OLECTRA IN) - Nov 2025 1. Primer: SG Mart (SGMART IN) - Nov 2025 SG Mart is rapidly expanding its B2B marketplace for building materials, primarily focusing on steel, with an aggressive growth strategy aiming to capture a significant share of the large and fragmented Indian market. The company benefits from the strong backing of the APL Apollo Group, providing it with industry relationships, funding, and brand leverage for its B2C distribution. Key risks include the highly competitive nature of the steel trading industry, which operates on thin margins, and the volatility of steel prices, which can impact profitability. This content is AI-generated and displayed for general informational purposes only.

Brief India: APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics and more

In this briefing: APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics Why Biocon's Merger Is the Cleaner, Cheaper Path to Value Unlock? Primer: Sagar Cements (SGC IN) - Nov 2025 Primer: Olectra Greentech (OLECTRA IN) - Nov 2025 The Beat Ideas: DISA India - Engineering the Next Decade of Indian Foundries 1. APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics Leads Biolabs initiated Phase 2 clinical study evaluating LBL-024 for the first-line treatment of HCC. Henlius Biotech got FDA approval for Poherdy, as the first interchangeable biosimilar to Roche’s Perjeta. Otsuka announced positive Phase 3 interim analysis of sibeprenlimab for immunoglobulin A nephropathy. ABL Bio signed technology transfer and joint R&D agreement with Eli Lilly for upfront payment of $40M. Boryung Pharmaceutical began construction to double its oral penicillin production capacity. Eubiologics published positive result from Phase 3 clinical trial evaluating EuTYPH-C, a typhoid conjugate vaccine. 2.

Sagar Cements Ltd. engages in the business of cement and cement related products. The company was founded by V. Butchaiah, Papagari Muni Krishna, and J. Rama Rao on January 15, 1981 and is headquartered in Hyderabad, India.

Current Price	163.52
Prev Close	165.00
Open	160.00
Dividend Yield	0.00%
50-Day Moving Average	185.13
Beta	-0.07
Avg. Volume	143,903.53
PE Ratio	-12.66

52-Week High	299.40
52-Week Low	148.70
Market Capitalization	21.34B
EPS (Annual)	-16.05
Price to Book	1.28
Revenue Per Employee	18.39M

SAGCEM.NSE
Sagar Cements Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest SAGCEM.NSE News

SAGCEM.NSESagar Cements Ltd.